The news. The narrative. The timeline.
Bureau: Chicago
Novo's pill is a record-breaking start at $354M and 2M scripts; Lilly's Foundayo prints week four into a 24-to-1 ratio and an RBC bar of 90,000 fills by week 12.
Three days after the print, Pfizer's full-year guide assumes no 2026 buybacks against $3.3B unused — the most aggressive disciplined-capital line in pharma.
Week four came in at 7,335 — a 31 percent increase off the 5,612 baseline, and still on the wrong side of the math that gets Lilly to a $1.4 billion FY model.
Sweden's 95,000-person semaglutide cohort says depression risk drops 44 percent; a propensity-matched comparator says it rises — and both designs sit next to a two-million-script U.S. base.
Utah's outbreak holds at 638 cases — 441 in 2026 — and a May 6 Lancet letter names the U.S. 'highly likely' to lose elimination status when PAHO meets in November.
Day 3 of APHIS's lactating-dairy testing exemption — Idaho still holds 17-plus confirmed dairies in quarantine while the artificial-insemination vector hypothesis stays unresolved.
Day 9 of a peer-reviewed Science paper showing the CDC's revised autism page measurably lowers vaccination intent and amplifies science-denial reasoning in 3,000 adults.
AHA's April 23 tribute and NHLBI's May 5 director message frame Braunwald as 'father of modern cardiology' — the same week federal cardiology research budgets are being cut.
Becle's Q1 net profit fell 67 percent and U.S. sales 36.6 percent — Cinco's Day 4 receipt is the world's largest tequila maker hitting the holiday on a distributor switch, not a tailwind.